Indefinite Delivery Contract SPE2DR25D9329

The federal contract IDV awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $4,999,999 single-award Indefinite Delivery Contract (IDC) covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

The original solicitation, the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), aims to establish multiple regional prime vendor contracts to provide worldwide pharmaceutical support to the Defense Health Agency (DHA), Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The $30.3 billion acquisition is structured as a firm-fixed-price, requirements-type contract with a 30-month base period and three 30-month option periods, awarded on a lowest price technically acceptable basis. The contract will enable the DLA to issue delivery orders for a diverse array of pharmaceutical products to support normal day-to-day operations, planned and unplanned contingency, Prime Vendor Readiness (PVR), and War Readiness Materiel (WRM) requirements at both CONUS and OCONUS locations.